Pilot to Evaluate the Safety and Efficacy of Abatacept in Adults and Children Over the Age of 6 With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) - Trial 2015-005450-36
Access comprehensive clinical trial information for 2015-005450-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb Company and is currently status unknown. The study focuses on Rheumatoid Arthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-005450-36
Trial Details
EU Clinical Trials Register • 2015-005450-36
Pilot to Evaluate the Safety and Efficacy of Abatacept in Adults and Children Over the Age of 6 With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Study Focus
Sponsor & Location
Bristol-Myers Squibb Company
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
• Kidney diseases other than FSGS or MCD
ICD-10 Classifications
Rheumatoid arthritis, unspecified
Other rheumatoid arthritis
Other specified rheumatoid arthritis
Rheumatoid arthritis with involvement of other organs and systems
Seronegative rheumatoid arthritis
Data Source
EU Clinical Trials Register
2015-005450-36
Non-Device Trial